Cipla's remdesivir Cipremi launched in India for Covid-19 Tr
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Cipla has launched the generic version of COVID-19 treatment drug remdesivir at a price which is among the lowest globally, according to a PTI report.

"We are proud to commercially launch Cipremi today; amongst the lowest priced globally, and aim to supply over 80,000 vials within the first month itself," Cipla Executive VP and CEO (India Business) Nikhil Chopra said in an e-mailed statement.

To further ensure equitable distribution, the drug will be available through government and hospital channels only, he added.

Cipremi has been approved by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need.

In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.

Source: https://www.livemint.com/news/india/coronavirus-vaccine-cipla-launches-generic-version-of-remdesivir-in-india-11594223346722.html
Dr. I●●●●●●E G●●●A and 10 others like this3 shares
Like
Comment
Share